MedTrace Logo

Identification of Diagnostic And Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples

NCT01948102 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 132

Last updated 2022-04-26

No results posted yet for this study

Summary

The purpose of the project is to obtain skin and adipose tissue samples from patients with ALS to develop new diagnostic and prognostic markers of the disease. These samples will be obtained when percutaneous endoscopic gastrostomy (PEG) is performed as part of their standard of care. Skin and adipose tissue samples will also be obtained from disease control subjects who require a PEG as part of their standard of care.

Conditions

Sponsors & Collaborators

  • ALS Therapy Development Institute

    collaborator OTHER

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Benjamin R Brooks, MD · Carolinas Neuromuscular/ALS-MDA Care Center

  • Thomas Pacicco, MD · Gastroenterology

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-20
Primary Completion
2014-08-06
Completion
2017-04-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01948102 on ClinicalTrials.gov